无数经验教训告诉我们，预期打得太满，往往不是什么好事 ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 10 Stocks Crash Hard Alongside Wall Street. Apogee Therapeutics fell by ...

Investing.com - Jefferies周二将Apogee Therapeutics Inc (NASDAQ: APGE )的目标价从88.00美元上调至96.00美元，同时维持对该股的"买入"评级。这一新目标价与分析师的普遍共识一致， InvestingPro 数据显示分析师目标价在78美元至116美元之间，而该股目前交易价格为39.24美元。

Investing.com - Canaccord Genuity在Apogee Therapeutics Inc (NASDAQ: APGE )特应性皮炎治疗药物取得积极临床试验结果后，重申了其买入评级和89.00美元的目标价。该目标价较当前39.24美元的价格有显著上涨空间， InvestingPro 数据显示分析师目标价在78美元至116美元之间，反映了市场多方共识。

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot ...

President Donald Trump has signed House Resolution 1 (H.R. 1), the final version of which does not impose a moratorium on state legislation governing the use of AI. The bill does, however, restore the ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...